NCT05904236 - Safety and Tolerability of Intravenous Administration of ICVB-1042 | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 1, 2023

Primary Completion Date

December 11, 2024

Study Completion Date

December 20, 2024

Conditions

Patients With Advanced Solid Tumors

Interventions

DRUG

Treatment with ICVB-1042 administered intravenously

Part A Dose Escalation to assess safety and tolerability of ascending dose levels, define the maximum tolerated dose (MTD), and expansion dose(s) Part B Dose Expansion to further assess safety and tolerability of 1 or more dose levels

Trial Locations (10)

10016

NYU Langone Health, Perlmutter Cancer Center, New York

19104

University of Pennsylvania, Abramson Cancer Center, Philadelphia

22031

Next Oncology, Virginia, Fairfax

27599

University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill

28078

Carolina BioOncology, Huntersville

37203

Sarah Cannon Research Institute, Nashville

48201

Karmanos Cancer Institute, Detroit

75039

Next Oncology, Dallas, Irving

78229

Next Oncology, San Antonio, San Antonio

92069

California Cancer Associates, San Marcos